Compare iShares China Large-Cap ETF (FXI) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Natera Inc. Common Stock — how do they compare? iShares China Large-Cap ETF trades at $33.72 (market cap $3.93B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 14.5× iShares China Large-Cap ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 151 Days and Natera Inc. Common Stock for 0 Days on average.
| FXI | NTRA | |
|---|---|---|
Market Cap | $3.93B | $57.03B |
Volume | 14,707,409 | 1,131,157 |
52-Week High | $41.08 | $425.64 |
52-Week Low | $31.59 | $179.42 |
Typical Hold Time | 151 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI, the iShares China Large-Cap ETF, trades at $34.17 with minimal daily movement (+0.09%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. Recent news highlights China's mixed economic signals, including strong corporate profit growth but concerns over industrial overcapacity and trade tensions. The ETF offers value exposure with a P/E ratio approximately half that of the S&P 500, but faces significant geopolitical and economic headwinds.
The outlook for FXI remains clouded by US-China relations and domestic economic challenges. Investment opportunity lies in its valuation discount versus US equities and potential policy support from Chinese authorities. Key risks include escalating trade protectionism, weak domestic consumption, and regulatory uncertainty. Analyst sentiment is divided, reflecting the high-risk, high-reward nature of Chinese large-cap exposure.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
